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Introduction: Children with asthma often have normal spirometry despite significant disease.
The pathology of the small airways in asthma may be assessed using Multiple Breath Washout
(MBW) and calculating the Lung Clearance Index (LCI). There are only few studies using MBW in
children with asthma and existing data regarding bronchodilator effect are contradictory. The
aim of the present pilot study was to compare LCI in asthma and controls and assess the effect
of salbutamol in children with asthma on the LCI.
Methods: Unselected patients with a diagnosis of asthma visiting the outpatient department of
our hospital between 04-2010 and 03-2011 were recruited and compared to a healthy control
group. MBW was performed as inert gas MBW using sulfurhexafluorid (SF6) as the tracer gas.
Clinical data were documented and spirometry and MBW (EasyOne Pro, MBW module, NDD
Switzerland) were performed before and after the use of salbutamol (200e400 mg). Healthy
controls performed baseline MBW only.
Results: 32 children diagnosed with asthma (4.7e17.4 years) and 42 controls (5.3e20.8) were
included in the analysis. LCI differed between patients and controls, with a mean LCI (SD) of
6.48 (0.48) and 6.21 (0.38) (P Z 0.008). Use of salbutamol had no significant effect on LCI for
the group.
Conclusion: These pilot data show that clinically stable asthma patients and controls both have
a LCI in the normal range. However, in patients the LCI is significantly higher indicating that
MBW may have a role in assessing small airways disease in asthma.
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MBW in paediatric asthma 1255IntroductionAsthma is the most common chronic respiratory disease
in children and is characterised by airway inflammation
and bronchial hyperresponsiveness. Most of the structural
changes in asthma have, until recently, been described
in the large airways. In recent years the important role
of small airway disease in asthma has increasingly been
appreciated. Lung tissue obtained from surgical resec-
tion, autopsy or biopsy show more extensive inflamma-
tion and airway remodelling in the peripheral airways
compared to the central airways [1e3]. Even in pre-
school children too young to perform spirometry,
airway remodelling has been demonstrated [4]. Current
guidelines regarding diagnosis and management base
their recommendations on symptoms and spirometry,
although it is now widely accepted that spirometry is not
sensitive and there is often little correlation between
airway inflammation and symptoms or airway inflamma-
tion and airway obstruction measured with spirometry
[5,6]. Standard spirometry provides information of
obstruction in the large, central airways, but is an
insensitive measure for the peripheral airways, unless
gross changes are present [7,8]. There is evidence that
the small airways may be reflected in Multiple Breath
Washout (MBW) and the Lung Clearance Index (LCI). In
Cystic Fibrosis (CF), LCI has a higher sensitivity than
spirometry for measuring extent and progression of lung
disease [9,10]. In asthma, changes of the LCI are likely
to be more subtle. Existing data found that the LCI is
significantly elevated compared to healthy controls, but
is still within the normal range. It can therefore not be
used to diagnose asthma on an individual level [10e12].
Results regarding bronchodilator response on LCI in
paediatric asthma patients are contradictory. In younger
patients a significant effect on FEV1 was seen, without a
change in LCI. One study with older children showed no
improvement of LCI, whereas Gustafsson et al. showed a
small improvement of LCI after the administration of
salbutamol [10,12e14].
The primary objective of this pilot study was to assess
the LCI and the effect of salbutamol on LCI in paediatric
asthma patients. We hypothesized that the LCI is more
sensitive to assess small airways changes in children with
asthma than spirometry. Secondary aims were to compare
the LCI of paediatric asthma patients to healthy controls,
and to assess the association between standard spirometry
(FEV1) and LCI.
Methods
Study design
This is a prospective, cross-sectional observational pilot
study in an unselected group of children and adolescents
with asthma compared to a healthy control group, where
MBW was measured in both, patients and controls. In pa-
tients, spirometry and MBW were compared pre- and post
inhalation of salbutamol.Setting and participants
Measurements were performed at the Department of Pae-
diatrics of the Marien Hospital Wesel between April 2010
and March 2011.
Patients were recruited from the asthma outpatient
department and were eligible if they had a confirmed
diagnosis of asthma and a minimum age of four years.
Exclusion criteria were presence of other severe or chronic
lung diseases, exacerbations in the last 6 weeks or changes
in asthma medication over the last 6 weeks. Outpatients in
a stable clinical state were recruited prior to their
following routine visit to the department. The study was
then incorporated into the routine diagnostic workup for
those patients who agreed to participate.
MBW measurements previously derived from healthy
children and adolescents using the same protocol, equip-
ment and software for analysis were used as the reference
data set [15,16]. Definition of a healthy individual excluded
diagnosis of asthma, presence of other severe or chronic
(lung) diseases, prematurity and presence of other severe
diseases.
The study was approved by the ethics committee of the
Medizinische Hochschule Hannover. Informed written
parental consent and if applicable children’s assent were
obtained prior to the measurements.
Protocol
All asthma patients aimed to perform a set of 2e3 techni-
cally acceptable MBW measurements plus subsequent
spirometry. Measurements were performed pre and post
200e400 mg of inhaled salbutamol. Post-bronchodilator lung
function testing started after an interval of 10e15 min
according to the ATS/ERS standard [17]. Healthy controls
only performed a baseline MBW.
Demographic data were obtained and documented prior
to the measurements. Additional clinical information
regarding severity of asthma and degree of asthma control
according to the GINA guidelines, current medical treat-
ment and results of the Asthma Control Test (ACT) were
obtained from outpatient records [5].
For children between 4 and 11 years of age the child-
hood ACT was used. Children older than 12 years of age
received the adult ACT.
MBW
MBW measurements were performed using the EasyOne
Pro, MBW Module (NDD Medical Technologies, Zurich,
Switzerland). The ultrasonic technology was described
elsewhere [18].
Briefly, the system consists of a side stream ultrasonic
transducer for temperature and humidity independent
sampling of the molar mass (MMss), a mainstream ultrasonic
transducer for flow sampling and a side stream infrared CO2
analyser (DUET ETCO2 Module, Welch Allyn OEM Technolo-
gies, Beaverton) to correct the MMss signal for exhaled CO2.
The gas bias flow system provides valve-controlled tracer
Table 1 Patient characteristics.
Asthma
(n Z 32)
Healthy volunteers
(n Z 42)
P
Agea 11.3 (4.7e17.4) 12.1 (5.3e20.8) 0.220
Maleb 19 (59.4) 12 (28.6) 0.007
Heighta 148.9 (109e178) 155.2 (109e184) 0.407
Weighta 38.4 (18.2e67.1) 40.3 (16.3e79.0) 0.341
LCIc 6.48 (0.48) 6.21 (0.38) 0.008
Two-tailed P-values below 0.05 were regarded as statiscally
significant.
a Median (range).
b Absolute number (%).
c Mean (SD).
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oxygen and balanced nitrogen. WBreathª software (NDD,
Switzerland) was used for data acquisition, storage and
analysis. Following visual quality control, LCI and functional
residual capacity (FRC) are automatically calculated ac-
cording to published procedures that are implemented into
the software.
LCI is defined as the number of lung volume turnovers
needed until the lungs are cleared from the inert tracer gas
that has been inhaled before. An increased LCI (>7.0) in-
dicates ventilation inhomogeneity [19] and thus, changes in
peripheral airways.
MBW measurements were performed in a sitting posi-
tion, breathing through a mouth piece, and wearing a nose
clip. The patients watched a video during the test proce-
dure to facilitate a regular breathing pattern. Pulse oxim-
etry was used for monitoring oxygen saturation and heart
rate during the measurement.
After 10 breaths of room air, the wash-in phase is started
by switching the device to the tracer gas at end expiration.
Having reached equilibrium, patients are switched back
into room air to start the washout phase. The washout
phase is defined to be complete when the SF6 concentration
has fallen below 2.5% (1/40) of the starting level.
All MBW tests underwent visual quality control before
analysis. Predefined quality control criteria for a technical
acceptable test were the following:
- Regular tidal breathing.
- Stable plateau of the side stream molar mass signal at
the 4%-SF6-level indicating end of wash-in phase.
- Stable plateau of the side stream molar mass signal at
the room-air-level indicating end of wash-out phase.
- Absence of a leak.
At least two technical acceptable MBW tests pre- and
post-bronchodilator were required for including the
participant into final analysis.
Spirometry
Measurements were performed according to ERS/ATS
criteria using the Master Screen Bodyplethysmograph
(Carefusion, Germany) [17]. Curves were accepted or dis-
carded after visual inspection. Subsequently, the best
curves were selected according to FVC and FEV1, while FET
was no criterion for acceptability.
Results of the best manoeuvre were documented and
used for final analysis. Spirometry was performed after
MBW.
Statistics
Demographic data such as age, weight and height are re-
ported as median and range. Categorical data were ana-
lysed using the Fisher exact or Chi square test. Continuous
data were compared using the independent samples t-test
or the ManneWhitney test, depending on the distribution of
the data.
Individual data for LCI are reported as median and
interquartiles of 2e3 technically acceptable washoutmanoeuvres for each subject. According to published
normal data obtained in healthy children and adolescents
and with the same equipment used in this study, the upper
limit of normal for the LCI was 7.0.
Within-test repeatability is defined as the variability of
LCI in an individual and is derived from the 3 or at least 2
single washout manoeuvres within one test occasion.
Within-test repeatability is expressed as the intra individual
coefficient of variation (CV%) that is defined as (SD/Mean)
*100.
Spirometric parameters are expressed as z-scores ac-
cording to the Global Lung Initiative (www.lungfunction.
org) [20]. Improvement of 12% FEV1 was considered as a
positive bronchodilator response.
The statistical package used was SPSS version 20.0 for
Windows.
Results
Fourty-two Children and adolescents with asthma and 42
healthy controls derived from our reference population
participated in the study and performed a pre-
bronchodilator MBW [16]. Ten patients were excluded: In
7 patients there was not enough time to perform a post-
bronchodilator MBW, 2 did not meet the diagnostic
criteria for asthma and in 1 patient the clinical data were
lost. Comparative spirometry was successful in 30/32 pa-
tients. The data of the 2 patients who failed the spirometry
were used to compare MBW between asthma patients and
healthy controls, but were excluded in the pre- and post-
bronchodilator analysis.
Patient characteristics
Demographic data are shown in Table 1. There were no
statistical differences with regard to age, height and weight
between the patients and controls. In the asthma group
significantly more males were included compared to the
group with healthy controls (P Z 0.007).
Table 2 shows the characteristics of the asthma patients.
According to the Gina criteria [5], 13/32 patients had
controlled asthma, 13 were partly controlled and 4 un-
controlled. Median (range) ACT-score in children <12 years
was 25 (19e27) and 23.5 (14e25) in patients >12 years. 2
patients scored less than 19 on the ACT. 22/32 patients
Table 2 Characteristics asthma patients.
Asthma n Z 32
Corticosteroid useb
None 10 (31.3)
Low 9 (28.1)
Medium 12 (37.5)
High 1 (3.1)
ACT
<12 years (n Z 11)a 25 (19e27)
>12 years (n Z 14)a 23.5 (14e25)
Missing (n Z 7)
Score  19b 2 (8)
GINAb
Controlled 13 (40.6)
Partly controlled 13 (40.6)
Uncontrolled 4 (12.5)
Unknown 2 (6.3)
a Median (range).
b Absolute number (%).
Figure 1 Individual LCI versus age in 32 patients with asthma
and 42 controls. The line represents the upper limit of normal
(7) for the LCI.
Table 3 Lung function parameters in asthma patients pre-
and post-bronchodilator.
Pre-
bronchodilator
(n Z 30)
Post-
bronchodilator
(n Z 30)
P
FEV1%
predicteda
99.7 (14.4) 106.3 (13.7) <0.001
FEV1 z-score
a 0.02 (1.21) 0.53 (1.14) <0.001
FEF75 z-scorea 0.17 (1.25) 0.62 (1.28) 0.004
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according to the GINA guidelines 9 patients used a low dose,
12 a medium, and 1 a high dose of ICS. 9 of these patients
used a combination inhalation of a long acting b2- agonist
(LABA) and ICS [5]. Two patients used a LABA less than 12 h
before the visit to the outpatient department.
The interval between pre- and post-bronchodilator lung
function testing was 10e15 min according to international
standards.
The LCI differed significantly between patients and
controls, with mean LCI (SD) of 6.48 (0.48) and 6.21 (0.38)
(P Z 0.008) (Fig. 1). Within-test repeatability of the LCI
was 5.5% in patients and 5.1% in controls.
Mean lung function parameters of MBW and spirometry
in patients with asthma are listed in Table 3. The FEV1 and
FEF75 were well within the normal range for the group.
Only 4/42 patients had a FEV1 Z-score below e 1.64 SD.
However 3 of these patients had a normal LCI. 3/32 patients
had a slightly increased LCI in presence of a normal FEV1 in
2 of them (Fig. 2). No relation between the FEF75 and FEV1/
FVC and LCI were found.
The median difference, between pre- and post-bron-
chodilator FEV1 absolute and in percent (range) was þ0.1 L
(0.08 to þ0.58) and þ4.47% (2.60 to þ48.3) (P < 0.001)
respectively. The median (range) difference between pre-
and post-bronchodilator LCI was e 0.095 (1.22 to 1.02)
(P Z 0.152).
Spirometry revealed 4/30 patients with a bronchodilator
response of 12% increase in FEV1% predicted.
In these 4 patients with a positive bronchodilator
response, a LCI with a range 6.43e7.84 and 5.75e7.49
respectively was seen (P Z 0.068, difference ranging from
0.20 to 0.69).FEV1/FVC z-
scorea
0.10 (1.31) 0.38 (1.11) 0.051
LCIa 6.48 (0.48) 6.63 (0.52) 0.152
Two-tailed P-values below 0.05 were regarded as statiscally
significant.
a Mean (SD).Discussion
In this pilot study we compared the LCI, using SF6 as tracer
gas, between healthy controls and paediatric patients withclinically stable asthma. In patients, LCI pre- and post-
bronchodilator was assessed and compared with the effect
of salbutamol on spirometry. Children with asthma had a
significantly higher LCI compared to healthy controls which
persisted after salbutamol use. This is in agreement with
other research, and suggests that ventilation in-
homogeneity is present in the airways of patients even with
well controlled asthma and in the presence of normal
spirometry [10e12,14]. Therefore, MBW provides different
information than spirometry and may have a role in
assessing small airways disease in asthma. However, as re-
ported by Keen et al. and Macleod et al. mean LCI for the
group was within the normal range [11,12].
Figure 2 Individual LCI versus FEV1 z-score in 30 patients
with asthma. The horizontal line represents the upper limit of
normal (7) for the LCI; The vertical line represents the lower
limit of normal (1, 64 SD) for the FEV1.
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with healthy controls. Therefore, the relevance of
measuring the LCI in clinical routine remains questionable.
However, several studies showed the weak correlation be-
tween FEV1% predicted and asthma symptoms and severity.
Normal FEV1% predicted may be observed at all levels of
severity [6,19,21]. Ventilation inhomogeneity, reflected by
the LCI, is supposed to measure changes in peripheral air-
ways not apparent using spirometry. Other parameters of
ventilation inhomogeneity using the slope analysis may be
better suited to differentiate changes in the most periph-
eral airways. Unfortunately, the equipment and software
used for the present study does not allow slope analysis. In
addition, it may be interesting to measure the LCI in better
defined or more severe paediatric asthma populations to
further investigate the usefulness of the LCI for assessing
small airways in paediatric asthma.
In well controlled asthma patients with a normal FEV1 a
small statistically significant raise within the normal vari-
ability in FEV1, FEF75 and FEV1/FVC was seen after the use
of a bronchodilator. The fact that only a small change in
spirometric parameters is observed is probably due to the
use of inhalation ICS leading to controlled asthma in the
majority of our patient population.
Although a significant change in spirometry was seen we
did not observe a change in the LCI. This is in line with the
known effect of salbutamol on Beta2-receptors in lung tis-
sue, leading to smooth muscle relaxation. This effect is
mainly observed in the large airways (>generation 8), and
has probably little effect on the small airways as reflected
by the LCI. Therefore, the absence of an effect on the LCI
possibly reflects residual small airways changes consistent
with previous observations in MBW studies and biopsies in
children with asthma [2,4,11,12].
When analysing the data of the four children with a
positive bronchodilator response, a decrease in the LCI wasseen. The decrease in LCI in this small subpopulation sug-
gests that only a large improvement of airway obstruction
leads to decrease of ventilation inhomogeneity in the small
airways. Because the effect was already evident in
spirometry there seems to be no additional value of
measuring the LCI in this small group of children.
This study has several limitations. Firstly, for this pilot
study, a heterogeneous group of asthma patients was
included. Most of these patients were well controlled with
maintenance therapy with ICS, with or without LABA. This is
reflected by the normal mean FEV1 z-score measured in our
patients. Only four patients had a FEV1 z-score <1.64 SD,
with 3 of them having a LCI in the normal range. 3 patients
had a slightly elevated LCI and of these, 2 had a normal
FEV1 z-score. It is therefore not surprising that there was no
correlation between the FEV1 z-score and LCI. Secondly,
the dosage of salbutamol for the bronchodilator test was
relatively low and varied between 200 and 400 mg according
to the local protocol. Thirdly, the interval between pre-
and post-bronchodilator test was 10 min only, which is the
lower limit of our standard operating procedure (SOP) for
spirometry and in accordance with international standards
[17]. However the study of Kaik showed that after 10 min
89% of the peak effect of salbutamol is reached [22].
Therefore the effect of salbutamol was not maximal and
the effect on the LCI may have been underestimated.
Thirdly, our healthy subjects performed MBW, but did not
perform spirometry. A similar subclinical difference in
spirometry between asthma patients and concurrent local
healthy control subjects can not be excluded. However,
equipment, team and analysis software were similar for
healthy subjects and patients included in the present study.
We are therefore confident, that the observed difference is
real and reflects subtle changes in small airways not
apparent using spirometry.
Finally, the study was performed with prototype equip-
ment still using SF6 as the tracer gas. Since then, equip-
ment has been developed further and gas washout switched
to nitrogen washout. Therefore, the results observed in this
pilot study may not be transferrable to other, current
equipment.
In conclusion, this pilot study shows that clinically sta-
ble paediatric patients with asthma have a significantly
higher LCI on average as healthy controls, the LCI still
being in the normal range. In this heterogenic patient
population with mostly mild asthma no difference was seen
for the LCI pre- and post-bronchodilator application. Only
in a small subgroup of patients with a positive bronchodi-
lator response a decrease in LCI was observed. These re-
sults again support the role of small airway disease in
paediatric patients with asthma. Ideally, further studies
have to be conducted in better defined patient groups,
possibly with more severe asthma, to explore the (clinical)
relevance of our findings.Funding
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